We develop MRI and multimodality biomarkers for Parkinson’s disease and related neurodegenerative conditions. There is a pressing need for improved measures of disease biology for applications in translational research and clinical diagnosis. We take an interdisciplinary approach to develop innovative MRI technologies and combine these with other data types (clinical assessments, neurocognitive testing, metabolomics, other molecular markers) to discover and validate new disease markers and signatures. To accomplish this, Dr. Huddleston's lab works closely with technical experts in MRI physics, image processing, machine learning, metabolomics and biomedical informatics. Dr. Huddleston's background in movement disorders neurology, Parkinson’s disease biology, and MRI methods allows us to investigate complex aspects of disease mechanisms, with the ultimate goal of improving patient care.